TR201903234T4 - Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. - Google Patents

Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. Download PDF

Info

Publication number
TR201903234T4
TR201903234T4 TR2019/03234T TR201903234T TR201903234T4 TR 201903234 T4 TR201903234 T4 TR 201903234T4 TR 2019/03234 T TR2019/03234 T TR 2019/03234T TR 201903234 T TR201903234 T TR 201903234T TR 201903234 T4 TR201903234 T4 TR 201903234T4
Authority
TR
Turkey
Prior art keywords
disease
pharmaceutical solution
parkinson
treatment
solution containing
Prior art date
Application number
TR2019/03234T
Other languages
English (en)
Inventor
Devos David
Moreau Caroline
Laloux Charlotte
Christophe Devedjian Jean-
Original Assignee
Centre Hospitalier Regional Et Univ De Lille
Univ Du Littoral Cote Dopale
Univ Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional Et Univ De Lille, Univ Du Littoral Cote Dopale, Univ Lille filed Critical Centre Hospitalier Regional Et Univ De Lille
Publication of TR201903234T4 publication Critical patent/TR201903234T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş, Parkinson hastalığını tedavi etmeye yönelik olarak en azından dopamin içeren farmasötik çözelti ile ilgili olup, burada söz konusu farmasötik çözelti, formülasyonundan uygulamasına kadar anaerobik koşullar altında tutulmaktadır.
TR2019/03234T 2014-05-13 2015-05-12 Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. TR201903234T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1454254 2014-05-13
EP15305352 2015-03-09

Publications (1)

Publication Number Publication Date
TR201903234T4 true TR201903234T4 (tr) 2019-03-21

Family

ID=53059131

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03234T TR201903234T4 (tr) 2014-05-13 2015-05-12 Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.

Country Status (15)

Country Link
US (2) US10105326B2 (tr)
EP (2) EP3142651B1 (tr)
JP (2) JP6496815B2 (tr)
AU (2) AU2015260953B2 (tr)
BR (1) BR112016026422A2 (tr)
CA (1) CA2947474C (tr)
DK (2) DK3142651T3 (tr)
ES (2) ES2943567T3 (tr)
FI (1) FI3453388T3 (tr)
HU (1) HUE042456T2 (tr)
IL (2) IL274203B2 (tr)
PL (1) PL3142651T3 (tr)
PT (1) PT3142651T (tr)
TR (1) TR201903234T4 (tr)
WO (1) WO2015173258A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113876697A (zh) * 2021-09-26 2022-01-04 武汉久安药业有限公司 一种盐酸多巴胺的注射液及其制备工艺
WO2024056749A1 (en) 2022-09-14 2024-03-21 Inbrain Pharma Pharmaceutical injectable solution comprising dopamine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR114796A (fr) 1876-10-03 1876-12-02 Demouchy A M Manches de pelles courbes
JPH11128314A (ja) * 1997-10-28 1999-05-18 Kyowa Hakko Kogyo Co Ltd シリンジ製剤
FR2832063B1 (fr) * 2001-11-15 2004-08-27 Aguettant Lab Procede de production de solutions stables de substances phenoliques et les solutions en resultant
JP2008068122A (ja) 2007-11-01 2008-03-27 Kyowa Hakko Kogyo Co Ltd シリンジ製剤
JP2012001493A (ja) * 2010-06-17 2012-01-05 Terumo Corp 塩酸リトドリン注射製剤
MX2012012559A (es) 2012-10-29 2014-04-28 Patricia Vergara Aragon Composicion de tio2/dopamina implantada en el cerebro de la rata para el tratamiento del hemiparkinsonismo.

Also Published As

Publication number Publication date
IL248672B (en) 2020-05-31
US20170151193A1 (en) 2017-06-01
IL274203B2 (en) 2023-12-01
US10105326B2 (en) 2018-10-23
ES2714726T3 (es) 2019-05-29
JP6496815B2 (ja) 2019-04-10
NZ725828A (en) 2023-10-27
JP2019085421A (ja) 2019-06-06
WO2015173258A1 (en) 2015-11-19
IL274203B1 (en) 2023-08-01
AU2020203126A1 (en) 2020-06-04
PT3142651T (pt) 2019-03-21
HUE042456T2 (hu) 2019-06-28
AU2015260953B2 (en) 2020-02-27
CA2947474A1 (en) 2015-11-19
EP3453388B1 (en) 2023-02-15
DK3142651T3 (en) 2019-03-25
AU2020203126B2 (en) 2021-07-15
IL274203A (en) 2020-06-30
EP3453388A1 (en) 2019-03-13
CA2947474C (en) 2022-05-17
JP2017515905A (ja) 2017-06-15
EP3142651B1 (en) 2018-12-12
JP7475113B2 (ja) 2024-04-26
DK3453388T3 (da) 2023-04-24
FI3453388T3 (fi) 2023-05-09
EP3142651A1 (en) 2017-03-22
AU2015260953A1 (en) 2016-11-17
BR112016026422A2 (pt) 2017-12-05
PL3142651T3 (pl) 2019-07-31
US20190022034A1 (en) 2019-01-24
IL248672A0 (en) 2017-01-31
ES2943567T3 (es) 2023-06-14

Similar Documents

Publication Publication Date Title
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
EA201890204A1 (ru) Антибактериальные соединения
EA201990043A1 (ru) Антибактериальные соединения
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692109A1 (ru) Варианты антител к фактору d и их применение
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
CL2015002897A1 (es) Inhibidores de bace1
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
BR112017003705A2 (pt) compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
EA201692392A1 (ru) Новая лекарственная форма мелоксикама
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201790315A1 (ru) Модуляторы x-рецепторов печени
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
MD4763B1 (ro) Compoziţie farmaceutică
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.
EA201790973A1 (ru) A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
MX2016008968A (es) Compuestos organicos.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds